Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial
Yi Pan, Xuening Yang, Qing Zhou, Yanqiu Zhao, Guang Han, Qingsong Pang, Zhenfa Zhang, Qifeng Wang, Jun Yao, Hui Wang, Weihua Yang, Baogang Liu, Qixun Chen, Xianghui Du, Kaican Cai, Baosheng Li, Yunchao Huang, Xiao Li, Yijun Jia, Li Song, Wei Shi, Yi-Long Wu · 2026
Read Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial by Yi Pan, Xuening Yang, Qing Zhou, Yanqiu Zhao, Guang Han, Qingsong Pang, Zhenfa Zhang, Qifeng Wang, Jun Yao, Hui Wang, Weihua Yang, Baogang Liu, Qixun Chen, Xianghui Du, Kaican Cai, Baosheng Li, Yunchao Huang, Xiao Li, Yijun Jia, Li Song, Wei Shi, Yi-Long Wu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13272590.txt.
Description
Yi Pan leads updated 2026 results from the TRAILBLAZER phase 2 trial in stage III lung cancer that could not be removed at first. The drug tested, retlirafusp alfa, blocks two signals at once, PD-L1 and TGF-beta. Patients got it before surgery or radiation, with or without chemotherapy, based on PD-L1 level.
At a median follow-up of 39.4 months, three-year event-free survival was 50.5 percent in the combined chemotherapy arms and 77.1 percent with the drug alone. Among 27 patients who had surgery, three-year survival was 84.9 percent. No new safety problems appeared, and the authors back this response-guided approach for further study.
Catalog record
| CREATOR | Yi Pan, Xuening Yang, Qing Zhou, Yanqiu Zhao, Guang Han, Qingsong Pang, Zhenfa Zhang, Qifeng Wang, Jun Yao, Hui Wang, Weihua Yang, Baogang Liu, Qixun Chen, Xianghui Du, Kaican Cai, Baosheng Li, Yunchao Huang, Xiao Li, Yijun Jia, Li Song, Wei Shi, Yi-Long Wu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31448 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |